Review discusses AI improving drug safety and efficacy assessment, highlighting future implications for pharmacovigilance.
This review discusses the application of AI in drug safety and efficacy assessment, highlighting its potential to improve clinical trial outcomes. AI techniques analyze vast datasets to predict adverse events, treatment responses, and operational risks. Despite high performance in studies, challenges such as data bias and limited generalizability remain. Addressing these issues can enhance drug development efficiency and patient safety. AI is poised to play a crucial role in future pharmacovigilance and personalized medicine.
No takes yet. Share an insight, caveat, or question.
Patidar* et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: